| Dr Robert William Stetekluh, OD | |
|
4238 Wilson Blvd, Suite 3140, Arlington, VA 22203-1823 | |
| (703) 524-2800 | |
| (703) 524-9493 |
| Full Name | Dr Robert William Stetekluh |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 39 Years |
| Location | 4238 Wilson Blvd, Arlington, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164576005 | NPI | - | NPPES |
| 06-1711971 | Other | VA | TAX ID # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 0618001004 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| David M. Goldberg, O.d., P.c. | 9335266949 | 2 |
News Archive
Carnegie Mellon University's Philip LeDuc predicts the use of artificially created cells could be a potential new therapeutic approach for treating diseases in an ever-changing world.
Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.
Diabetes is the number 1 cause of neuropathy, which is a very common condition in itself. In fact, up to half of all neuropathy is caused by diabetes, although other people can get the condition as well.
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer's disease suggests a new focus for research into the causes of the disease.
› Verified 6 days ago
| Provider Name | New Era Eyecare Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1801108576 PECOS PAC ID: 3577696657 Enrollment ID: O20100727000846 |
News Archive
Carnegie Mellon University's Philip LeDuc predicts the use of artificially created cells could be a potential new therapeutic approach for treating diseases in an ever-changing world.
Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.
Diabetes is the number 1 cause of neuropathy, which is a very common condition in itself. In fact, up to half of all neuropathy is caused by diabetes, although other people can get the condition as well.
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer's disease suggests a new focus for research into the causes of the disease.
› Verified 6 days ago
| Provider Name | David M. Goldberg, O.d., P.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1932334497 PECOS PAC ID: 9335266949 Enrollment ID: O20111121000388 |
News Archive
Carnegie Mellon University's Philip LeDuc predicts the use of artificially created cells could be a potential new therapeutic approach for treating diseases in an ever-changing world.
Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.
Diabetes is the number 1 cause of neuropathy, which is a very common condition in itself. In fact, up to half of all neuropathy is caused by diabetes, although other people can get the condition as well.
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer's disease suggests a new focus for research into the causes of the disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert William Stetekluh, OD 6301 Little River Tpke, Ste 110, Alexandria, VA 22312-5044 Ph: (703) 524-2800 | Dr Robert William Stetekluh, OD 4238 Wilson Blvd, Suite 3140, Arlington, VA 22203-1823 Ph: (703) 524-2800 |
News Archive
Carnegie Mellon University's Philip LeDuc predicts the use of artificially created cells could be a potential new therapeutic approach for treating diseases in an ever-changing world.
Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.
Diabetes is the number 1 cause of neuropathy, which is a very common condition in itself. In fact, up to half of all neuropathy is caused by diabetes, although other people can get the condition as well.
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer's disease suggests a new focus for research into the causes of the disease.
› Verified 6 days ago
Elizabeth Ann Lobaugh, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3800 N Fairfax Drive, Suite 1, Arlington, VA 22203 Phone: 703-522-3454 Fax: 703-522-9636 | |
Dr. Stephan Eugene Hanowsky, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1100 S Hayes St, Arlington, VA 22202 Phone: 703-415-5544 | |
Jeff C. Chuh, O.d. Optometrist Medicare: Medicare Enrolled Practice Location: 1654 Crystal Square Arc, Arlington, VA 22202 Phone: 703-413-9001 Fax: 703-552-1334 | |
My Eye Dr. Optometrist Medicare: Medicare Enrolled Practice Location: 4121 Wilson Blvd Ste 100, Arlington, VA 22203 Phone: 703-525-7474 Fax: 703-525-4108 | |
Dr. Daniel O Olanrewaju, O.D Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1100 S Hayes St, Suite 3042, Arlington, VA 22202 Phone: 571-483-0033 Fax: 703-416-9591 | |
Dr. Ume K Chowhan, OD Optometrist Medicare: Medicare Enrolled Practice Location: 2823 Clarendon Blvd, Arlington, VA 22201 Phone: 703-294-6600 |